Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Executive Editor, Pharma Insights
UK
+32 year(s) experience
Having graduated in modern languages at the University of Bath in 1979, he worked in the European travel industry before joining Scrip World Pharmaceutical News as a reporter in 1985, covering the French and Italian markets. He later became Deputy Editor with responsibility for EU regulatory affairs, a post he held until 2005 when he took on the role of Consultant Editor to a number of Informa publications including Scrip and the Regulatory Affairs Journal.
In July 2008 Ian became a Principal Analyst for Informa Business Information, covering global regulatory and legal issues in areas such as clinical trials, biosimilars, orphan drugs, and pricing and reimbursement. As well as writing news, features and analysis for Scrip Intelligence, Scrip Regulatory Affairs, the Pink Sheet and In Vivo, Ian is part of the Ask the Analyst team that produces on-demand tailored reports for subscribers.
Pink Sheet
By Ian Schofield 31 Aug 2017
Recent evidence indicates that using DAAs together with warfarin, a vitamin K antagonist, may result in changes in the INR.
Topic Drug review
Pink Sheet
By Ian Schofield 23 Aug 2017
A position paper from the UK government has laid out some ideas for ensuring a smooth transition to a post-Brexit world in the area of regulation.
Topic Brexit
Pink Sheet
By Ian Schofield 10 Aug 2017
Some countries in eastern Europe say that they should host the European Medicines Agency in order to respect the criterion of “geographical spread.”
Topic Brexit
Pink Sheet
By Ian Schofield 03 Aug 2017
Some regulatory activities have been on hold at the European Medicines Agency as it prepares for the impact of the UK’s departure from the EU.
Pink Sheet
By Ian Schofield 17 Jul 2017
Dublin will “absolutely” meet the criteria for hosting the European Medicines Agency.
Topic Biosimilars
Pink Sheet
By Ian Schofield 29 Jun 2017
Two generic industry associations have merged to form a single body that includes the largest generic companies in Ireland.
Topic Biosimilars
Pink Sheet
By Ian Schofield 15 May 2017
Complaints against pharmaceutical companies for imposing “excessive” prices on generic drugs is growing after the European Commission decided to pursue Aspen Pharma over price rises.
Pink Sheet
By Ian Schofield 26 Apr 2017
Speakers at a DIA EuroMeeting session on the challenges and opportunities facing regulators in the years to come discussed several options including more proactive engagement by regulators, more sharing by drug sponsors, and being innovative across the whole of the regulatory landscape.
Pink Sheet
By Ian Schofield 23 Apr 2017
The European Commission has produced draft Brexit negotiating directives in which it suggests that the UK should bear the cost of moving the European Medicines Agency from London to elsewhere in the EU.
Topic Brexit
Scrip
By Ian Schofield 18 Apr 2017
Many key biologic drugs, including adalimumab, bevacizumab, rituximab and trastuzumab, are facing biosimilar competition from products that have been either filed or recently approved in Europe.
Topic Biosimilars
Pink Sheet
By Ian Schofield 12 Apr 2017
Samsung Bioepis’s Brenzys has become the second biosimilar product to be reimbursed as substitutable at the pharmacy level in Australia.
Topic Reimbursement
Pink Sheet
By Ian Schofield 24 Mar 2017
Malta has joined the ever-growing number of countries wanting to host the European Medicines Agency when it relocates from the UK post-Brexit. The European Commission has said new “technical issues” have been raised that will need to be addressed, and industry bodies have outlined the criteria they say need to be met by the future host country.
Topic Brexit
Pink Sheet
By Ian Schofield 01 Mar 2017
The leader of Denmark’s bid to host the European Medicines Agency after the UK leaves the EU says that a rapid decision-making process on the agency’s new location is needed in order to avoid entanglements with the wider Brexit negotiations, and that a decision could be taken sometime in the second half of this year.
Topic Brexit
Pink Sheet
By Ian Schofield 10 Jan 2017
Professor Sir Michael Rawlins, chair of the MHRA, has told a UK committee of his concerns over Brexit, including possible delays in access to new drugs, a decline in revenues for regulatory work on behalf of the EU, and the possibility that some firms’ HQs might follow the European Medicines Agency if it relocates to another European country.
Topic Brexit Drug review
Pink Sheet
19 Sep 2017
Medtech Insight
18 Sep 2017
Pink Sheet
18 Sep 2017
Pink Sheet
15 Sep 2017
Pink Sheet
15 Sep 2017
Pink Sheet
15 Sep 2017
Scrip
15 Sep 2017
Pink Sheet
13 Sep 2017
Pink Sheet
11 Sep 2017
Pink Sheet
08 Sep 2017
Pink Sheet
08 Sep 2017
Pink Sheet
07 Sep 2017
Pink Sheet
07 Sep 2017
Pink Sheet
07 Sep 2017
Pink Sheet
05 Sep 2017
